Aspirin for the primary prevention of cardiovascular events: recommendation and rationale

This statement summarizes the recommendation of the third U.S. Preventive Services Task Force (USPSTF) for aspirin for the primary prevention of cardiovascular events, as well as the supporting scientific evidence. The complete information on which this statement is based, including evidence tables...

Full description

Saved in:
Bibliographic Details
Published inAnnals of internal medicine Vol. 136; no. 2; p. 157
Format Journal Article
LanguageEnglish
Published United States 15.01.2002
Subjects
Adult
Aged
Aspirin - adverse effects
Aspirin - therapeutic use
Chemoprevention
Coronary Disease - epidemiology
Coronary Disease - prevention & control
Evidence-Based Medicine
Female
Fibrinolytic Agents - adverse effects
Fibrinolytic Agents - therapeutic use
Humans
Male
Middle Aged
Primary Prevention
Risk Factors
United States - epidemiology
United States
Online AccessGet more information

Cover

More Information
Summary:This statement summarizes the recommendation of the third U.S. Preventive Services Task Force (USPSTF) for aspirin for the primary prevention of cardiovascular events, as well as the supporting scientific evidence. The complete information on which this statement is based, including evidence tables and references, can be found in a companion article in this issue. Copies of this document, the summary of the evidence, and the systematic evidence review can be obtained through the USPSTF Web site (http://www.ahrq.gov/clinic/uspstfix.htm) and in print through the Agency for Healthcare Research and Quality Publications Clearinghouse (800-358-9295).
ISSN:1539-3704
DOI:10.7326/0003-4819-136-2-200201150-00015